Special Issue "Evolving Paradigm of Curative Intent Breast Cancer Management"
Deadline for manuscript submissions: closed (30 April 2022) | Viewed by 12629
Interests: clinical trials; value of novel therapeutics
The care of breast cancer has evolved significantly over the past decade, with personalized medicine and biomarkers influencing decision-making in the curative setting. Within each breast cancer receptor subtype (hormone receptor positive, HER-2 positive, and triple-negative), recent advances are influencing the sequencing of curative therapy. Studies are assessing both escalation and de-escalation of treatment intensity in specific sub-groups of patients. Additional research suggests adjunct lifestyle interventions (such as exercise) also can play a significant role in improving treatment tolerance and compliance, while also impacting cancer outcomes.
This special issue will focus on the current status and challenges in treating breast cancer in the curative setting. It will encompass therapeutic advances in systemic therapy for breast cancer across the receptor subtypes as well as radiotherapy. The role of adjunct lifestyle interventions (both during and after treatment), to help improve the care of breast cancer patients, will also be reviewed.Dr. Patricia Tang
Dr. Jeffrey Cao
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Breast neoplasms
- Carcinoma, ductal, breast
- Carcinoma, lobular
- Triple negative breast neoplasms
- Estrogen antagonists
- Estrogen receptor modulators
- Genomic testing
- HER-2 positive breast cancer
- Hormone-receptor positive breast cancer
- Breast Surgery/Axillary Surgery